Clinical Trial Update: Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ublituximab plus ibrutinib versus ibrutinib alone in previously treated high-risk chronic lymphocytic leukemia has completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• Ublituximab (ublituximab)

Snippet

Sponsor: TG Therapeutics, Inc. | Conditions: Chronic Lymphocytic Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2022-05-20